Where eosinophilic esophagitis treatment is heading
Eosinophilic esophagitis · Updated Nov 13, 2026
Eosinophilic esophagitis is an allergic inflammation of the esophagus that makes swallowing hard and can cause food to get stuck. It affects about 1 in 2,000 people and is rising. Options are acid blockers, swallowed steroids, food elimination and dupilumab; more antibodies are close.
- 54studies open or running
- 3phase 3 trials
- 432papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
Dupilumab works from age 1Happened 68% tissue remission
68% of young children reached tissue remission on the higher dose vs 3% with placebo.
68%: in tissue remission on the higher dose, vs 3% with placebo.
Milk-only diet is enough to startHappened 41% remission, milk-only
One-food elimination matched four-food elimination (41% vs 44%) with fewer dropouts.
41%: remission with milk elimination alone, vs 44%.
Removing eosinophils is not enoughHappened
Benralizumab cleared eosinophils but did not ease swallowing.
-
6 months
by May 2027
Tezepelumab filingLikely
CROSSING met both goals; AstraZeneca and Amgen plan to share data with regulators.
-
12 months
by Nov 2027
Acid blocker and steroid injection resultsPossible
Trials of vonoprazan and EP-104GI, a long-acting steroid injected into the esophagus, report in 2026–2027.
-
3 years
by late 2029
More antibody choicesPossible
Tezepelumab, cendakimab and solrikitug could add options for people who do not respond to dupilumab.
-
5 years
by late 2031
Pills for hard casesLong shot
A UNC trial tests upadacitinib, a JAK pill, for EoE that resists other treatments.
The research paths
Antibodies
68% tissue remissionDetails and 1 trialsHide
Blocking IL-13 and TSLP, the signals upstream of eosinophils.
WatchTezepelumab filing.
Pills, injections and diet
41% remission, milk-onlyDetails and 3 trialsHide
Simpler diets, stronger acid blockers, long-acting steroids and JAK pills.
WatchVonoprazan and EP-104GI.
Borrowed from other conditions
From Severe asthma
Tezepelumab
Phase 3 positive
An anti-TSLP antibody approved for asthma and nasal polyps.
From Acid reflux
Vonoprazan
Phase 2
A stronger acid blocker than standard PPIs.
Open to join now
-
Adults
EP-104GI injection
Locations and eligibility → -
Not responding to other treatment
Upadacitinib
Locations and eligibility → -
Small children
Dupilumab
Locations and eligibility →
See every recruiting EoE trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Tezepelumab meets both goals
CROSSING phase 3.
Cendakimab phase 3 positive
NEJM Evidence.
Standard treatment today
- First treatmentProton pump inhibitor, swallowed steroid (budesonide), or food elimination.
- Not respondingDupilumab injections; switching or combining first-line options.
- Narrowing (strictures)Esophageal dilation plus anti-inflammatory treatment.
How to read this page, and sourcesHow to read this page, and sources
- Tissue remission and symptom relief do not always move together; trials now measure both.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See EoE trials recruiting now →